$4.57
1.56%
NYSE, Oct 24, 10:00 pm CET
ISIN
US7133171055
Symbol
PEPG

PepGen Stock price

$4.57
+1.91 71.80% 1M
+2.89 172.02% 6M
+0.78 20.58% YTD
-3.66 44.47% 1Y
-4.90 51.74% 3Y
-8.32 64.55% 5Y
-8.32 64.55% 10Y
-8.32 64.55% 20Y
NYSE, Closing price Fri, Oct 24 2025
+0.07 1.56%
ISIN
US7133171055
Symbol
PEPG
Industry

Key metrics

Basic
Market capitalization
$314.1m
Enterprise Value
$239.5m
Net debt
positive
Cash
$74.7m
Shares outstanding
32.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
78.6%
Return on Equity
-75.9%
ROCE
-119.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-101.3m | $-101.4m
EBIT
$-102.8m | $-104.6m
Net Income
$-96.9m | $-87.1m
Free Cash Flow
$-90.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-7.3% | -5.4%
EBIT
-7.3% | -7.1%
Net Income
-8.7% | 3.3%
Free Cash Flow
-20.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-2.8
Short interest
7.4%
Employees
62
Rev per Employee
$0.0
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a PepGen forecast:

10x Buy
83%
1x Hold
8%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a PepGen forecast:

Buy
83%
Hold
8%
Sell
8%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
16% 16%
-
- Research and Development Expense 80 80
5% 5%
-
-101 -101
7% 7%
-
- Depreciation and Amortization 1.48 1.48
2% 2%
-
EBIT (Operating Income) EBIT -103 -103
7% 7%
-
Net Profit -97 -97
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Seeking Alpha
19 days ago
PepGen Inc. (PEPG) has seen its DM1 trials advance to phase 2 with a great reaction from markets. PEPG discontinued its DMD trials, which explains some of the reduced R&D expenses in the last 3 months and also some of the stock's declines earlier in the year. With only $45 million in net cash and marketable securities and maybe towards $1 billion in future R&D costs, potential equity raises wit...
Neutral
24/7 Wall Street
20 days ago
In the past week or so, some public offerings of stock prompted big insider buying.
Neutral
Business Wire
25 days ago
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company's data will be presented in two oral presentations at the 30th Annual International Congress of the World Muscle Socie...
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 62
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today